University of Utah   

Are there particular patient characteristics (e.g. age, ER%, Ki67, grade) that make you more likely to choose neoadjuvant endocrine therapy?

How do clinical risk and Mammaprint/Oncotype scores affect your decision?

Patient case is triple positive inflammatory breast cancer

Of note, the patient received cytotoxic plus HER2 directed adjuvant therapy but declined endocrine therapy. 

For example, is this still your approach in women with small tumors or node negative disease?

If yes, would you still recommend dual HER2 directed therapy? After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...

Provided the sternal lesion was low volume and treated with curative intent and patient has been on tamoxifen for < 5 years, would you switch to AI...

If so, after how many cycles of chemotherapy would you switch?

I.e. according to Mammaprint test?

The CALOR trial included patients that could receive HER2-targeted therapy.

Initial pathology additionally yields low Ki-67 and is HER2 negative. 

Pt is healthy and tolerating Tamoxifen well. 

Would you do this for ER+ patients? According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...

If so, how frequently?

First episode was 10 years ago and patient did not receive XRT. Would you give XRT now? 

An article (BRCA mutation and outcome in BC. Ellen Copson, et al. Lancet Oncol. 2018) showed G3, BRCA+ breast cancer had poorer prognos...